Acumen pharmaceuticals collaborates with lonza to advance sabirnetug for the treatment of alzheimer's disease

Charlottesville, va. and basel, switzerland, april 04, 2024 (globe newswire) -- acumen pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), has signed a collaboration agreement with lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets. the agreement covers the manufacture of sabirnetug (acu193), an antibody targeting toxic soluble aΒos for the treatment of ad, for clinical development and commercialization, if approved.
ABOS Ratings Summary
ABOS Quant Ranking